<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cefixime: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cefixime: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cefixime: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9216" href="/d/html/9216.html" rel="external">see "Cefixime: Drug information"</a> and <a class="drug drug_patient" data-topicid="12294" href="/d/html/12294.html" rel="external">see "Cefixime: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F147405"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Suprax [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866237"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Auro-Cefixime;</li>
<li>Suprax</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1045954"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Cephalosporin (Third Generation)</span></li></ul></div>
<div class="block dop drugH1Div" id="F147427"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Unless otherwise specified, any dosage form may be used. Oral suspension is available in multiple concentrations; use caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing; susceptible infection (mild to moderate):</b> Infants, Children, and Adolescents: Oral: 8 mg/kg/day once daily or in divided doses every 12 hours; maximum daily dose: 400 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64ff1343-c15e-4fb6-8514-daa594a50ebd">Febrile neutropenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Febrile neutropenia (low-risk):</b> Limited data available: Infants, Children, and Adolescents: Oral: 8 mg/kg/day once daily or in divided doses every 12 hours; in most trials, cefixime therapy was initiated as step-down therapy after 48 to 72 hours of empiric parenteral antibiotic therapy with first cefixime dose administered at the end of the last IV infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11037850','lexi-content-ref-28459614','lexi-content-ref-10870071','lexi-content-ref-11112678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11037850','lexi-content-ref-28459614','lexi-content-ref-10870071','lexi-content-ref-11112678'])">Ref</a></span>). <b>Note:</b> In clinical trials, doses were repeated if patient vomited within 2 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="94275df2-6a9f-438b-8861-72052261fd09">Gonococcal infection, uncomplicated infections of the cervix, urethra, or rectum</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gonococcal infection, uncomplicated</b>
<b>infections of the cervix, urethra, or rectum (alternative agent): </b>Children ≥45 kg and Adolescents: Oral: 800 mg as a single dose. If chlamydial infection has not been excluded, give as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33332296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33332296'])">Ref</a></span>). <b>Note:</b> Cefixime should only be used if ceftriaxone is unavailable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33332296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33332296'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3ab65aa5-1c14-484a-8cfb-f1fe4746f705">Irinotecan-associated diarrhea, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Irinotecan-associated diarrhea, prophylaxis:</b> Limited data available: Infants, Children, and Adolescents: Oral: 8 mg/kg once daily; begin 5 days before oral irinotecan therapy and continue throughout course (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17570704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17570704'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a96b8104-65d0-48ba-b460-4308464e6db6">Otitis media, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute (alternative agent):</b> Oral suspension or chewable tablets: Infants, Children, and Adolescents: Oral: 8 mg/kg/day once daily or in divided doses every 12 hours; maximum daily dose: 400 mg/<b>day</b>. <b>Note:</b> Not preferred therapy; may be considered in combination with clindamycin in certain scenarios after failure of first-line agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23439909']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23439909'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1437b55a-5145-4c15-bba4-c28709c37109">Rhinosinusitis, acute bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, acute bacterial (alternative agent):</b> Infants, Children, and Adolescents: Oral: 8 mg/kg/day once daily or in divided doses every 12 hours with concomitant clindamycin for 10 to 14 days; maximum daily dose: 400 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3320921','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3320921','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> Not first-line therapy; may be considered after failure of initial therapy or in patients with non-type I penicillin allergy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23796742','lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23796742','lexi-content-ref-22438350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="002747a1-d12d-413d-9efb-492e8da1743e">Streptococcus, group A; pharyngitis/tonsillitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcus, group A; pharyngitis/tonsillitis (alternative agent for nonanaphylactic penicillin allergy): Note:</b> Narrow-spectrum cephalosporins (eg, cephalexin) are preferred over broad-spectrum cephalosporins such as cefixime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 8 mg/kg/day once daily or in divided doses every 12 hours for 10 days; maximum daily dose: 400 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1454432','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1454432','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="549b2f99-20fe-4254-ae67-47dd86cf704b">Typhoid fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Typhoid fever (</b>
<i>
<b>Salmonella typhi</b></i>
<b>):</b> Limited data available; efficacy results variable: Infants, Children, and Adolescents: Oral: 15 to 20 mg/kg/day in divided doses every 12 hours for 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10093945','lexi-content-ref-7567290','lexi-content-ref-18057480','lexi-content-ref-11840084','lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10093945','lexi-content-ref-7567290','lexi-content-ref-18057480','lexi-content-ref-11840084','lexi-content-ref-WHO.1'])">Ref</a></span>). <b>Note:</b> Usual adult dose is 100 to 200 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1736b9da-16f1-43a4-91a2-afe554f7fb5a">Urinary tract infection, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, acute:</b> Infants ≥2 months, Children, and Adolescents: Limited data available in infants &lt;6 months: Oral: 8 mg/kg/day once daily or in divided doses every 12 hours for 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21873693','lexi-content-ref-3320921','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21873693','lexi-content-ref-3320921','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> Shorter courses (1 to 3 days) have been shown to be inferior to longer durations of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21873693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21873693'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51083992"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants ≥6 months, Children, and Adolescents: Very limited data available; some clinicians have suggested the following (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16133064','lexi-content-ref-1815970']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16133064','lexi-content-ref-1815970'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No adjustment recommended</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (eg, GFR ≤10 to 20 mL/minute/1.73 m<sup>2</sup>): Reduce dose by 50%</p>
<p style="text-indent:-2em;margin-left:4em;">Anuric: Reduce dose by 50%</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis, peritoneal dialysis: Not significantly removed</p></div>
<div class="block dohp drugH1Div" id="F51083993"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F147409"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9216" href="/d/html/9216.html" rel="external">see "Cefixime: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range:</b>
<b>Oral:</b> 400 mg/day divided every 12 or 24 hours.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="211497db-429c-4f08-a5f9-b2bc63113006">Gonococcal infection, uncomplicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gonococcal infection, uncomplicated (infection of the cervix, rectum [off-label use], or urethra) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use cefixime only if ceftriaxone cannot be used because cefixime is not as effective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 800 mg as a single dose; give in combination with treatment for chlamydia if it has not been excluded (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>). When treatment failure is suspected (eg, detection of <i>N. gonorrhoeae</i> after treatment without additional sexual exposure), consult an infectious diseases specialist. Report failures to the CDC through state and local health departments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98ea31cd-047b-4d50-8aa1-255f7149db3f">Gonococcal infection, expedited partner therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gonococcal infection, expedited partner therapy (off-label use):</b>
<b>Oral:</b> 800 mg as a single dose; give in combination with treatment for chlamydia if it has not been excluded (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>). <b>Note:</b> Expedited partner therapy (EPT) involves the delivery of medication and educational materials directly to a sex partner by the patient or collaborating pharmacy. Only use EPT if public health strategies are impractical/unavailable and there is concern that the partner will not otherwise get prompt evaluation and treatment. Use EPT with caution in men who have sex with men because of uncertain efficacy and lost opportunities for sexually transmitted infection/HIV risk assessment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1437b55a-5145-4c15-bba4-c28709c37109">Rhinosinusitis, acute bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, acute bacterial (alternative agent for patients with penicillin allergy who are able to tolerate cephalosporins) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In uncomplicated acute bacterial rhinosinusitis, initial observation and symptom management without antibiotic therapy is appropriate in most patients. Reserve antibiotic therapy for poor follow-up or lack of improvement over the observation period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25832968','lexi-content-ref-26785402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25832968','lexi-content-ref-26785402'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>400 mg once daily with clindamycin for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22438350'])">Ref</a></span>); some experts use as monotherapy when the risk of drug-resistant <i>S. pneumoniae</i> is low (eg, &lt;65 years of age, low endemic resistance, few comorbidities, no recent hospitalization or antibiotic use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Patel.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Patel.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="47f1db45-3ef1-4229-9b6c-df5d9de732de">Streptococcal pharyngitis, group A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcal pharyngitis, group A (alternative agent for mild, nonanaphylactic penicillin allergy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Cephalosporin selection depends on the type of hypersensitivity reaction to penicillin. To avoid the development of resistance, narrower spectrum cephalosporins (eg, cephalexin or cefadroxil) are preferred when possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026','lexi-content-ref-Pichichero.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026','lexi-content-ref-Pichichero.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 400 mg once daily for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026','lexi-content-ref-Pichichero.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026','lexi-content-ref-Pichichero.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="549b2f99-20fe-4254-ae67-47dd86cf704b">Typhoid fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Typhoid fever (off-label use):</b>
<b>Oral:</b> 100 to 200 mg twice daily for 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection (alternative agent): Note:</b> Use only when preferred agents cannot be used; limited evidence suggests inferior efficacy of oral beta-lactams (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21292654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cystitis, acute uncomplicated</i>
<i>or acute simple cystitis (infection limited to the bladder without signs/symptoms of upper tract, prostate, or systemic infection)</i>: <b>Oral:</b> 400 mg once daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21292654','lexi-content-ref-18061019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21292654','lexi-content-ref-18061019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urinary tract infection, complicated (including pyelonephritis):</i>
<b>Oral:</b> 400 mg once daily for 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21292654','lexi-content-ref-29298155','lexi-content-ref-26903277','lexi-content-ref-11777865']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21292654','lexi-content-ref-29298155','lexi-content-ref-26903277','lexi-content-ref-11777865'])">Ref</a></span>); for patients with symptomatic improvement within the first 48 to 72 hours of therapy, some experts recommend shorter courses of 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gupta.1','lexi-content-ref-30535100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gupta.1','lexi-content-ref-30535100'])">Ref</a></span>). <b>Note:</b> Oral therapy should follow appropriate parenteral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21292654'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990059"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Single-dose regimens (eg, 800 mg as a single dose) do not need to be dose adjusted for any degree of kidney dysfunction or type of renal replacement therapy. Renally adjusted dose recommendations are based on doses of 400 mg/day. Use only chewable tablets or oral suspension for patients with kidney dysfunction since unable to achieve recommended doses using capsules. Recommendations below are expert opinion derived from Dhib 1991, Guay 1986, and manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;20 to &lt;60 mL/minute: 300 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≤20 mL/minute: 200 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Limited dialyzability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3777912']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3777912'])">Ref</a></span>): 300 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Minimally dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3777912']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3777912'])">Ref</a></span>): 200 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>No data available; use of an alternative agent is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>No data available; use of an alternative agent is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987312"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer’s labeling. </p></div>
<div class="block adr drugH1Div" id="F147372"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&gt;10%: Gastrointestinal: Diarrhea (16%) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">2% to 10%: Gastrointestinal: Abdominal pain, nausea, dyspepsia, flatulence, loose stools </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&lt;2%: Acute renal failure, anaphylactoid reaction, anaphylaxis, angioedema, candidiasis, dizziness, drug fever, eosinophilia, erythema multiforme, facial edema, fever, headache, hepatitis, hyperbilirubinemia, increased blood urea nitrogen, increased serum creatinine, increased serum transaminases, jaundice, leukopenia, neutropenia, prolonged prothrombin time, pruritus, pseudomembranous colitis, seizure, serum sickness-like reaction, skin rash, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, urticaria, vaginitis, vomiting</p></div>
<div class="block coi drugH1Div" id="F147388"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to cefixime, other cephalosporins, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F147369"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic reactions: Severe cutaneous reactions (eg, toxic epidermal necrolysis, Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms [DRESS]) have been reported. If a reaction occurs, discontinue and institute supportive therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemolytic anemia: Immune-mediated hemolytic anemia (including fatalities) has been reported. Monitor patient (including hematologic parameters and drug-induced antibody testing when clinically appropriate) during and for 2 to 3 weeks after therapy. If hemolytic anemia occurs during therapy, discontinue use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity and anaphylaxis have been reported in patients receiving beta-lactam drugs. Use caution in patients with a history of hypersensitivity to cephalosporins, penicillins, or other beta-lactams. If administered to penicillin-sensitive patients, use with caution and discontinue use if allergic reaction occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal failure: May cause acute renal failure, including tubulointerstitial nephritis. If renal failure occurs, discontinue and initiate appropriate supportive therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>–associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; may increase the risk of seizures if dosage not reduced.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disease: Use with caution in patients with a history of GI disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemolytic anemia: Do not administer to patients with a history of cephalosporin-associated hemolytic anemia; recurrence of hemolysis is more severe.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: Chewable tablets contain phenylalanine; avoid use or use with caution in patients with phenylketonuria (PKU).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878374"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">May cause diarrhea; reported incidence (~16%) similar in children receiving oral suspension and adults receiving tablet dosage form. Use caution when interchanging product formulations; oral suspension and chewable tablets are bioequivalent but oral immediate release tablets are not bioequivalent; for some infections (eg, otitis media), dosing recommendations are product specific. </p></div>
<div class="block foc drugH1Div" id="F147381"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Suprax: 400 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 400 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Suprax: 100 mg/5 mL (50 mL [DSC]) [strawberry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Suprax: 200 mg/5 mL (50 mL [DSC], 75 mL [DSC]); 500 mg/5 mL (10 mL [DSC], 20 mL [DSC]) [contains sodium benzoate; strawberry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/5 mL (50 mL); 200 mg/5 mL (50 mL, 75 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Suprax: 100 mg [DSC], 200 mg [DSC] [contains aspartame, fd&amp;c red #40(allura red ac)aluminum lake; tutti-frutti flavor]</p></div>
<div class="block geq drugH1Div" id="F147365"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F6133204"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Cefixime Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $23.53 - $24.91</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Cefixime Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $4.45</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/5 mL (per mL): $8.91</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866238"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Suprax: 100 mg/5 mL (50 mL) [contains sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/5 mL (50 mL, 100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Suprax: 400 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 400 mg</p></div>
<div class="block admp drugH1Div" id="F52612380"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered with or without food; administer with food to decrease GI distress.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral suspension: Shake suspension well before use. Oral suspension is available in multiple concentrations; use precaution.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets, chewable: Must be chewed or crushed before swallowing.</p></div>
<div class="block adm drugH1Div" id="F147385"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">May be administered with or without food. Shake oral suspension well before use. Chewable tablets must be chewed or crushed before swallowing.</p></div>
<div class="block sts drugH1Div" id="F147400"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsule, chewable tablet: Store at 20°C to 25°C (68°F to 77°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Powder for suspension: Prior to reconstitution, store at 20°C to 25°C (68°F to 77°F). After reconstitution, suspension may be stored for 14 days at room temperature or under refrigeration.</p></div>
<div class="block usep drugH1Div" id="F53565923"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of urinary tract infections, otitis media, acute exacerbations of chronic bronchitis; treatment of pharyngitis and tonsillitis due to <i>Streptococcus pyogenes</i>; treatment of uncomplicated cervical/urethral gonorrhea due to <i>Neisseria gonorrhoeae</i> (All indications: FDA approved in ages ≥6 months and adults); has also been used for treatment of acute bacterial rhinosinusitis, management of irinotecan-associated diarrhea, and management of low-risk febrile neutropenia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Due to concerns of resistance, the CDC no longer recommends use of cefixime as a first-line regimen in the treatment of uncomplicated gonorrhea in the US; ceftriaxone is the preferred cephalosporin in combination with azithromycin (CDC 2012; CDC [Workowski 2015]).</p></div>
<div class="block mst drugH1Div" id="F147450"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cefixime may be confused with cefepime </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Suprax may be confused with Sporanox</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cefiton: Brand name for cefixime [Portugal] may be confused with Ceftim brand name for ceftazidime [Portugal]; Ceftime brand name for ceftazidime [Thailand]; Ceftin brand name for cefuroxime [US, Canada]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298989"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F147374"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May enhance the nephrotoxic effect of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F147401"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food delays cefixime absorption. Management: May administer with or without food.</p></div>
<div class="block dic drugH1Div" id="F147392"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Chewable tablets contain phenylalanine; avoid use or use with caution in patients with phenylketonuria (PKU).</p></div>
<div class="block pri drugH1Div" id="F5951284"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Cefixime crosses the placenta and can be detected in the amniotic fluid (Ozyüncü 2010).</p>
<p style="text-indent:0em;margin-top:2em;">An increased risk of major birth defects or other adverse fetal or maternal outcomes has generally not been observed following use of cephalosporin antibiotics.</p></div>
<div class="block mopp drugH1Div" id="F53565922"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">With prolonged therapy, monitor renal and hepatic function periodically; number and type of stools/day for diarrhea. Observe for signs and symptoms of anaphylaxis during first dose.</p></div>
<div class="block pha drugH1Div" id="F147368"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>
<div class="block phk drugH1Div" id="F147387"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Chewable tablets and oral suspension are bioequivalent. However, oral suspension and capsule formulation are <b>not</b> considered bioequivalent.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Absorption: 40% to 50%; <b>Note:</b> Capsule AUC reduced by ~15% and C<sub>max</sub> by ~25% when taken with food.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely throughout the body and reaches therapeutic concentration in most tissues and body fluids, including synovial, pericardial, pleural, peritoneal; bile, sputum, and urine; bone, myocardium, gallbladder, and skin and soft tissue</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 65%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Normal renal function: 3 to 4 hours; Moderate impairment (CrCl 20 to 40 mL/minute): 6.4 hours; Renal failure: Up to 11.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Suspension: 2 to 6 hours; Capsule: 3 to 8 hours; Delayed with food</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (50% of absorbed dose as active drug); feces (10%)</p></div>
<div class="block phksp drugH1Div" id="F51192715"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Average AUCs at steady state in elderly patients are ~40% higher than average AUCs in healthy adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i> Time dependent; associated with time free drug concentration (fT) &gt; minimum inhibitory concentration (MIC): Goal: ≥40% to 50% (fT) &gt; MIC (bacteriostatic), ≥60% to 70% (fT) &gt; MIC (bactericidal) (Craig 1996; Craig 1998; Owens 2001; Turnidge 1998).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Expected drug exposure in normal renal function:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric patients, C<sub>max </sub>(peak): Single dose: Oral: 8 mg/kg:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥2 months of age and children ≤2 years of age: 3.1 ± 1.8 mg/L (Nahata 1993).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥6 years of age and adolescents ≤13 years of age: 4.04 ± 1.51 mg/L (Mamzoridi 1996).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults, C<sub>max</sub> (peak):</p>
<p style="text-indent:-2em;margin-left:8em;">Single dose: 400 mg: 3.85 to 4.4 mg/L (Brittain 1985; Faulkner 1988).</p>
<p style="text-indent:-2em;margin-left:8em;">Steady state: 400 mg once daily: 4.74 ± 1.43 mg/L.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Generally &lt;1 hour; varies based on organism (Craig 1991; Craig 1998; Dubois 2000).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F147393"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apex | Cefim | Cefix | Dynaceph | Ixime | Magnacef | Ranpime | Suprax | Taxim o | Winex</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cefixima Fabra | Cefixima richet | Cefixime ilab | Cimacefi | Novacef | Vixcef</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Aerocef | Cefixim Hexal | Tricef</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">3 C | 3-Geocef | Afix | Afixime | Amucef | Antima | Bactazim | Bestcef | Bioxim | Cef 3 | Cefadyl | Cefcil | Cefesta | Ceficap | Cefim-3 | Cefix | Cefixim | Cefmix | Cefocef | Ceftid | Cefurex | Cephoral | Cexime | D fix | Defim 3 | Duracef | Elexim | Emixef | Excef | Fexim | Fix A | Fixbac | Fixpro | G-fix | Gen-3 | Infa-3 | Kefim | Keor | Kuracef | Loxim | Microcef | Odacef | Ofex | Onefix | Orcef | Orfix | Orgaxim | Prexim | Prioxim | Profix | Rofixim | Roxim | Sanfix | Saver | Starcef | Sufix | Supraxim | T cef | Texit | Tgocef | Tocef | Tricef | Trifix | Triocef | Triocim | Trixim | Truso | Tyfax 3 | Unifix | Velofix | Verixim | Ximbac | Xylocef | Zenicef</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Asmoxime | Ceficap | Cefix | Cefolac | Cielcef | Intercef | Mephixime | Ofiken | Oroken | Solexim | Sufix | Tocfim | Umexim</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cefixim actavis | Cefixime abr | Neocef | Pancef | Zefacet</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Neo cefix | Plenax</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cephoral</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Asmoxime | Bestcef | Brufix | C tax p | Cefaxe | Cefexol | Ceficap | Cefim | Cefiron | Cefix | Cefixime sp | Cefolac | Cielcef | Ebuxime | Eficef | Fixim | Fixinect | Fixiser | Intercef | Megacef | Melcef | Ofiken | Oroken | Sanix | Secef | Solexim | Sufix | Taxim o | Theofix | Tocfim | Win md | Zexim | Zexim ds</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cefspan | Tricef | Urotricef</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">An de ke wei | An di ke tuo | An di ke wei | Ao de ning | Bi you su | Cefspan | Da li fen | Fu xin kang | Han guang tuo | Heng da fei | Hui xin sha | Ji da xi fu | Jida xi fu | Jiu bang | Jun te | Kang pai | Ke li luo | Ke lin dun | Ke wo sha | Kui ke | Luo wei ke | Nuo bai you | Ou jian | Qi an | Qin ke wo | Qing ke yi | Sai fu mei | Shi fu su | Si li jie | Suprax | Te pu ning | Xin da xin | Xin fu su | Yan yi | Yu shu | Zai wo</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cefixima | Denvar | Devoxim | Gynoblen</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cefixime innfarm | Suprax</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aerocef | Cefixdura | Cefixim 1 A Pharma | Cefixim al | Cefixim Al 100mg/5ml | Cefixim Beta | Cefixim ct | Cefixim Hexal | Cefixim ratiopharm | Cefixim Sandoz | Cefixim Stada | Cefixim-ratiopharm | Ceftoral | Cephoral | Infectoopticef | Suprax | Uro cephoral</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Betaxima | Caulis | Cefimax 5d | Cefixima | Defixim | Denvar | Eticefa | Eurocefa 3 | Fixem | Fixim | Orobact | Probacter | Unocef | Zidicef</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cefixima | Denvar | Fixim | Longacef</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cefixdura</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cefabrum | Cefalotrigenex | Flavicef | Hebixime | Rivaxime | Suprax | Viodrilnex | Wideprex | Ximacef</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cefixima | Cefixima mabo | Cefixima Sandoz | Denvar | Necopen</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Bactofix | Cefimed | Cefix | Cefixime | Mahacef | Sanix | Winex</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Supracef</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cefixime actavis | Cefixime Almus | Cefixime arrow | Cefixime Biogaran | Cefixime cristers | Cefixime EG | Cefixime Evolugen | Cefixime mylan | Cefixime qualimed | Cefixime Ranbaxy | Cefixime Ratiopharm | Cefixime Teva | Cefixime Winthrop | Cefixime Zydus | Oroken</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Suprax</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ceftoral</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Cefexin | Cefiksim Jadran | Cefixim | Cefixim Alkaloid | Cefixim CLN</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Sufixin forte | Suprax</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Abixim | Anfix | Befixim | Cefacef | Cefarox | Cefika | Cefila | Cefspan | Ceptik | Cerafix | Cfx | Comsporin | Ethifix | Fixacep | Fixam | Fixatic | Fixef | Fiximca | Fixiphar | Helixim | Infix | Lanfix | Maxpro | Nucef | Opixime | Oracef | Pyxime | Simfix | Sofix | Spancef | Spaxim | Sporetik | Starcef | Suprax | Tocef | Trixim | Urticef | Ximecef | Yafix</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Suprax</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Supran</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">AB Cef | Acef | Acrotex | Acufix | Afixe | Akraxime | Alcef O | Almocef | Amicef | Ancef o | Anfix | Aucef | Axim-o | Axime | Axiom-or | Bafix | Bijocef | Biofix | Biotax-o | Bioxin | Brufix | Brutacef | C Let O | C Tax O | Cadixim | Cebay | Cedro CF | Ceefix | Ceemi | Cefal-o | Cefaxet | Cefi | Cefi od | Ceficad o | Ceficin | Ceficrat | Cefidoc | Cefiglen | Cefilab | Cefimed | Cefimo | Cefinar | Cefine | Cefio | Cefirap | Cefisuch | Cefix | Cefixain | Cefixinat | Cefkim | Ceflab | Cefluv | Cefma | Cefnij | Cefo | Cefocef O | Cefolac | Cefomarc-o | Cefoped | Cefox | Cefrax | Cefspan | Cefsung | Ceftas | Ceftiwin | Ceftobac | Cefxi O | Celitol | Cemax-o | Cf Xim | Cfx | Cifadin | Cifibac | Cifigold | Clasifix | Delbi | Desatax O | Dp | Dp cef | Efixim | Efixime | Efoxim | Elcef | Enzacef | Estacef | Esyfex | Evacef-o | Exim | Exime | Extacef | Feeximm | Femcef | Fevorit | Fexim | Fixi | Fixicom | Fixim | Fixime | Fixinic | Fixivio | Fixx | G Xime | Goldfin | Grafix | Gramocef o | Hhcefi | Hicef | Hifen | Hofim | Ifeoma | Ifixime | Indcef | Jetex | Kefotax O | Laricef o | Letix | Lupicef-o | Lyceft-o | Mahacef | Marixime | Maxicef o | Mdcef | Mefim | Micfox | Milixim | N cef | Necee | Nestocef | Nitaxim O | Novafex | O-powerceff | Obefex | Odicef-o | Omnatax-o | Omnix | Onicef Lb D T | Oraxim | Orfix | Oritaxim O | Pancef-o | Pedicef | Pedixim | Raxcef | Raxim O | Redicate | Refix | Rhoxim | Rintax O | Rite-O-Cef | S fix | Secef | Seffix | Segofix | Si Fixim | Siffy | Skifi | Speedoxime | Starfix | Sufax | Suprax | Swifix | Synercef | Synocef | Taxfax | Taxim o | Taxone-o | Topcef | Tox O | Traxol o | Trixon-o | Trusten o | U Fixim | Unitax O | Unocef | Vcef o | Verixime | Vexim | Wicef | Xecute | Xifbull | Xim | Xipil | Zafil | Zeefix | Zefix | Zencef | Zifi | Zimnic | Ziprax | Zofix | Zofixi | Zoftax o</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Acacime | Cefixime | Samaxime</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cefixima | Cefixima acv | Cefixima aurobindo | Cefixima Aurobindo Italia | Cefixima Doc | Cefixima EG | Cefixima Mylan | Cefixima Sand. | Cefixoral | Stadium | Supracef | Suprax | Unixime</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Apex | Betixim | Cefim | Cefix | Magnacef | Mixif | Pancef | Suprax | Winex</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cefspan | Cexim | Sefeena</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Aivxim | Bactifix | Biofix | Biozil | Biozil ds | C mark | C od | C tax p | C tax t | Cebay | Cef 3 ds | Cef 3 forte | Cef od | Cefatax o | Cefcy | Cefexol | Cefim | Cefiwel | Cefix | Cefiz | Ceflorex | Cefraz | Cefty | Cifex | Fimabute | Fix | Fixem | Fixem ds | Fixime | Fixinect | Flamifix | Gramocef o | Inoxime | Ixime | Mahacef | Nefexim | Orcef | Orfix | Pancef-o | Procefix | Raincef | Refixime | Rivaxime | Rofix | Seffix | Sirobact | Striaxime | Taxim o | Theofix | Triaxon | Triocim | Viprax | Xifix | Ximacef | Xime | Xime od | Zemicef | Zifax</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Apexim | Aprogen cefixime | Ausfixime | Binex cefixime | Cebixim | Cefacime | Cefaxamin | Cefick | Cefik | Cefimaxin | Cefime | Cefirax | Cefirexim | Cefirix | Cefix | Cefixime | Cefixime hanall | Cefixt | Ceforax | Cefra | Cefrion | Cefsin | Cemixim | Cepac | Ceprion | Ceracin | Cexime | Cifixim | Cifixime | Dong a suprax | Dongkoo cefixime hydrate | Dongsung cefixime | Efixim | Efixime | Eipecsim | Etex cefixime | Fixima | Fixtin | Fofix | Fofixime | Jr cefixime | Kukje cefixime | Kyungbang cefixime | Mothers cefixime | Nelson cefixime | Pocef | Reyon cefixime | Samsung cefixime | Senex | Seoul cefixime | Shinfixim | Sucef | Sufixime | Suprax | Unifixime | Unixim | Withus cefixime | Wonfixime</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Cefim | Cefix | Cefrax | Magnacef | Mixif | Suprax | Winex</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Betixim | Cefdia | Cefim | Cefix | Fixef | Fixim | Magnacef | Murex | Neocef | Suprax | Tox O | Winex</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Cefico | Ofiken | Oroken</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Amixbru | Bafexal | Beneventol | Biomics | Cefixima | Denvar</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cefix | Ixime | Minixime | Orfix | Yspcefixycin | Zifi</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Acofix | Afrixime | Bioxime | Brodcef | Cefest | Cefimax | Cefixime | Cefot | Clafix | Emzifix | Evofix | Ezcef | Gelxim | Ixime | Maydon cefixime | Meem cefixime | Mirafix | Nci cefixime | Sanfix | Surexime | Tamaxim | Zemicef | Zofixime</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cefixim ct | Cefixime dr reddys</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cefrom | Cimafix | Denvar | Maxefim</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Accefixime ds | Acecef | Actimax | Aeruxim | Afix | Amkofix | Argifix | Axetef | Bacticef | Bactixime | Beraxime ds | C tax p | Cefilim | Cefisal | Cefixmycin | Cefixsaph 100 | Cefolin plus ds | Cefsea | Cefzin | Cephoral | Cexime | Cifacure | Citroen | Comfixime | Dancef ds | Diaxime | Dyruxim | Elvofix | Eriexef | Evofix | Ezcef | Fexitas | Fimabute | Fix A | Fixbact | Fixcef | Fixcure | Fixim | Fixsil | Fixxx | Flamifix | Flexime | Gracefix | Ixime | Maedix | Myrecef | Ofex | Penxime | Refix | Refixime | Regecef | Retracef | Rexmecef | Robetrix | Sanix | Saphixime | Septipan | Soniceph | Sufice | Sunxime | Surixime | Synmex | Taxim o | Taxocef o | Tergecef | Trifixime | Trimax | Trinifix | Triocef | Triolev | Trufix | Typhofix | Ultraxime | Umexim | Unifix | Vamocef | Viprax ds | Vispoxime ds | Winfix | Zefaxim | Zefifarm | Zefitas | Zefixmed | Zefral | Zemfix</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Accumax | Aerocef | Afixim | Agrofix | Aksoxime | Akurate | Amber | Arco Fix | Arcofix suspension ds | Avecef | Bactirid | Baxacim forte | Bectazim | Benifix | Berxime | Bestar | Bestcef | Biozil | C mark | Carazime | Caricef | Cebosh | Cef od | Cefaim | Cefamax | Cefask | Cefexol | Cefgen | Cefia | Cefia duo | Cefial | Cefidon | Cefiget | Cefim | Cefipex | Cefipex ds | Cefirant | Cefiscot | Cefitax | Cefitest | Cefitol | Cefivant | Cefivel | Cefivid | Cefivid ds | Cefix | Cefkan | Cefkar | Ceflorex | Cefman | Ceforal-3 | Cefsel | Cefspan | Ceftas | Cefto | Cefzime | Cesave | Cestar | Cewel | Cexime | Cezox | Cezox ds | Cili cef | Cilicef | Cimonil | Cinklare | Cixim | Conspan | Corinef | Danxime | Devyn | Devyn ds | Dispel | Ds cefivid | Duet | Eficef | Efix | Epan | Epofix | Evofix | Exime | Fasxime | Fedixime | Ficsi | Finex | Fixcy | Fixef | Fixicef | Fixikef | Fixil | Fixim | Fixime | Fiximtas | Fixirin | Fixitil | Fixitil t | Fixval | Flexeril | Flozid | Fredixime | Genixime | Getxime | Gilspan | Gyala | Hefixim | Hispan | Hixime | Iboxime | Iboxime DS | If tar | Infix | Inxime | Isocef | Jencef | Kafixime | Kamcef | Kayfix | Lexime ds | Libroxime | Linzim | M span | Macxime | Magaxim | Magnett | Maxima | Maxophine | Maxpan | Medispan | Medixime | Medoxim | Mefixim | Megazime | Mimlux | Mixel | Mixime | Navexim | Nenxime | Nexcef | Nowcef | Omixim | Orcef | Orpase | Ortazim | Palxime | Palxime ds | Parsim | Pharxime | Procef | Rafix | Rayfix | Rayfix ds | Rayxime | Reyan | Ricxime | Rofil | Rutex | Ruwin | Ruwin ds | Sallar | Sayfim | Scifix | Seaxim | Secure | Sefixim | Septipan | Serve | Sivarol | Sixime | Sn xime | Snapcef | Solixim | Solixim ds | Spanix | Spaxime | Spectracef | Sporzim | Spril | Suncef | Superixime | Supracef | Suprin | Surexime | Swicef | Synocef | Tamcef | Theraxim | Tinocef | Triban | Trispan | Tycef | Tysen | Ur Cef | Vanil | Vefixim | Vencef | Vfix | Vg Span | Vimacef | Viospan | Vioxime | Vixime | Wizy | Xalfocin | Xeerak | Xerak | Xim | Xim ds | Ximbact | Xime c | Ximemor | Ximex | Xival | Xpertec | Y Fix | Zanxim | Zaxime | Ziac | Zifi | Zix | Zyacef | Zynoxim</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cephoral | Cetix | Suprax</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Suprax</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Bonocef | Cefimix | Cefiton | Cefixima | Cefixima aurobindo | Cefixima Baldacci | Cefixima Generis | Cefixima Germed | Cefixima Jaba | Neocef | Tricef</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Cefimex | Cefixiland | Cefixima caplin point | Cefixima cefen guayaki | Cefixima dallas | Cefixima dutriec | Cefixima genfar | Cefixima vivele | Celef | Ceprin | Cexima | Cimafix | Cimafix forte | Flupiral | Oralcef | Pedicepha</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Betixim | Cefix | Cefrax | Evofix | Fixef | Magnacef | Mixif | Suprax | Winex | Zycef</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cefixima aurobindo | Eficef | Suprax | Xifia</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cemidexor | Iksim | Ixime lupin | Pancef | Suprax</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Cefamax | Cefim | Cefix | Cefrax | Magnacef | Midixime | Mixif | Suprax | Winex</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Tricef</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Pancef</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cefimed | Cefixime innfarm | Suprax</span>;</li>
<li>
<span class="countryCode">(SY)</span> <span class="country">Syrian Arab Republic</span><span class="countrySeparator">: </span><span class="drugName">Nidaprax</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cefspan | Sixime</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cefoken | Faloxim | Megacef | Oroken</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cefdia | Cephix | Fixef | Molcef | Suprax | Zimaks</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ceficin | Cefixmycin | Cefspan | Cexim</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Cefinak | Cefixim Kmp | Fixx | Flamifix | Ixime | Loprax | Maxibat | Opticef | Sorcef | Suprax</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Cebay | Cef 3 | Cef 3 ds | Cefdia | Cefim | Cefimed | Cefiwel | Cefix | Cefraz | Fimabute | Fixime | Fixinect | Gramocef o | Sanix | Sanix ds | Sefixi | Taxim o | Topcef | Triaxon | Tryfix | Tryfix 100 ds</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Fiximax | Maxicef | Novacef | Oralcef | Supracef</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cefaspan | Cefixima | Defalox | Longacef | Unixime</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Bicebid | Daxame | Egofixim | Hafixim | Imexime | Infilong</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Exsef | Fixime</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">C tax p | Cebay | Cefix ds | Cefolac | Cifex | Fixinect | Gramocef o | Marixime | Orfix | Taxocef o | Zoocef</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21873693">
<a name="21873693"></a>American Academy of Pediatrics Subcommittee on Urinary Tract Infection. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. <i>Pediatrics</i>. 2011;128(3):595-610.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/21873693/pubmed" id="21873693" target="_blank">21873693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8229498">
<a name="8229498"></a>Ashkenazi S, Amir J, Waisman Y, et al. A Randomized, Double-Blind Study Comparing Cefixime and Trimethoprim-Sulfamethoxazole in the Treatment of Childhood Shigellosis. <i>J Pediatr</i>. 1993;123(5):817-821.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/8229498/pubmed" id="8229498" target="_blank">8229498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1454432">
<a name="1454432"></a>Block SL, Hedrick JA, Tyler RD. Comparative study of the effectiveness of cefixime and penicillin V for the treatment of streptococcal pharyngitis in children and adolescents. <i>Pediatr Infect Dis J</i>. 1992;11(11):919-925.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/1454432/pubmed" id="1454432" target="_blank">1454432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al. The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;53(7):e25-e76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4053491">
<a name="4053491"></a>Brittain DC, Scully BE, Hirose T, Neu HC. The pharmacokinetic and bactericidal characteristics of oral cefixime. <i>Clin Pharmacol Ther</i>. 1985;38(5):590-594. doi:10.1038/clpt.1985.229<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/4053491/pubmed" id="4053491" target="_blank">4053491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10093945">
<a name="10093945"></a>Cao XT, Kneen R, Nguyen TA, et al, A Comparative Study of Ofloxacin and Cefixime for Treatment of Typhoid Fever in Children. The Dong Nai Pediatric Center Typhoid Study Group, <i>Pediatr Infect Dis J</i>, 1999l18(3):245-248.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/10093945/pubmed" id="10093945" target="_blank">10093945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ascend.1">
<a name="Ascend.1"></a>Cefixime capsule [prescribing information]. Parsippany, NJ: Ascend Laboratories, LLC; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aurobindo.1">
<a name="Aurobindo.1"></a>Cefixime suspension [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA, Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9461053">
<a name="9461053"></a>Centers for Disease Control and Prevention (CDC). 1998 guidelines for treatment of sexually transmitted diseases. <i>MMWR Recomm Rep</i>. 1998;47(RR-1):1-111.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/9461053/pubmed" id="9461053" target="_blank">9461053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22438350">
<a name="22438350"></a>Chow AW, Benninger MS, Brook I, et al. IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults. <i>Clin Infect Dis</i>. 2012;54(8):e72-e112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/22438350/pubmed" id="22438350" target="_blank">22438350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9455502">
<a name="9455502"></a>Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.<i> Clin Infect Dis</i>. 1998;26(1):1-10. doi:10.1086/516284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/9455502/pubmed" id="9455502" target="_blank">9455502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craig.1">
<a name="Craig.1"></a>Craig WA. The postantibiotic effect. <i>CMNEEJ. </i>1991;13(16)121-128.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8852915">
<a name="8852915"></a>Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. <i>Pediatr Infect Dis J.</i> 1996;15(3):255-259. doi:10.1097/00006454-199603000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/8852915/pubmed" id="8852915" target="_blank">8852915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16133064">
<a name="16133064"></a>Daschner M. Drug dosage in children with reduced renal function. <i>Pediatr Nephrol</i>. 2005;20:1675-1686.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/16133064/pubmed" id="16133064" target="_blank">16133064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1815970">
<a name="1815970"></a>Dhib M, Moulin B, Leroy A, et al. Relationship between renal function and disposition of oral cefixime. <i>Eur J Clin Pharmacol</i>. 1991;41:579-583. doi:10.1007/BF00314988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/1815970/pubmed" id="1815970" target="_blank">1815970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3277054">
<a name="3277054"></a>Donowitz GR, Mandell GL. Beta-Lactam Antibiotics. <i>N Engl J Med</i>. 1988;318(7):419-26 and 318(8):490-500.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/3277054/pubmed" id="3277054" target="_blank">3277054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10904192">
<a name="10904192"></a>Dubois J, St-Pierre C. In vitro study of the post-antibiotic effect and the bactericidal activity of Cefditoren and ten other oral antimicrobial agents against upper and lower respiratory tract pathogens. <i>Diagn Microbiol Infect Dis</i>. 2000;37(3):187-193. doi:10.1016/s0732-8893(00)00141-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/10904192/pubmed" id="10904192" target="_blank">10904192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3203716">
<a name="3203716"></a>Faulkner RD, Bohaychuk W, Haynes JD, Desjardins RE, Yacobi A, Silber BM. The pharmacokinetics of cefixime in the fasted and fed state. <i>Eur J Clin Pharmacol.</i> 1988;34(5):525-528. doi:10.1007/BF01046715<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/3203716/pubmed" id="3203716" target="_blank">3203716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7567290">
<a name="7567290"></a>Girgis NI, Sultan Y, Hammad O, et al. Comparison of the Efficacy, Safety and Cost of Cefixime, Ceftriaxone and Aztreonam in the Treatment of Multidrug-Resistant <i>Salmonella typhi</i> Septicemia in Children. <i>Pediatr Infect Dis J</i>. 1995;14(7):603-605.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/7567290/pubmed" id="7567290" target="_blank">7567290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3777912">
<a name="3777912"></a>Guay DRP, Meatherall RC, Harding GK, et al. Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency. <i>Antimicrob Agents Chemother</i>. 1986;30(3):485-490. doi:10.1128/AAC.30.3.485<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/3777912/pubmed" id="3777912" target="_blank">3777912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gupta.1">
<a name="Gupta.1"></a>Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-e120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26785402">
<a name="26785402"></a>Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. <i>Ann Intern Med</i>. 2016;164(6):425-434. doi:10.7326/M15-1840<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/26785402/pubmed" id="26785402" target="_blank">26785402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1906097">
<a name="1906097"></a>Johnson CE, Carlin SA, Super DM, et al. Cefixime Compared With Amoxicillin for Treatment of Acute Otitis Media. <i>J Pediatr</i>. 1991;119(1):117-122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/1906097/pubmed" id="1906097" target="_blank">1906097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29298155">
<a name="29298155"></a>Johnson JR, Russo TA. Acute pyelonephritis in adults. <i>N Engl J Med</i>. 2018;378(1):48-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/29298155/pubmed" id="29298155" target="_blank">29298155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11037850">
<a name="11037850"></a>Klaassen RJ, Allen U, Doyle JJ. Randomized Placebo-Controlled Trial of Oral Antibiotics in Pediatric Oncology Patients at Low-Risk With Fever and Neutropenia. <i>J Pediatr Hematol Oncol</i>. 2000;22(5):405-411.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/11037850/pubmed" id="11037850" target="_blank">11037850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28459614">
<a name="28459614"></a>Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. <i>J Clin Oncol</i>. 2017;35(18):2082-2094.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/28459614/pubmed" id="28459614" target="_blank">28459614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Levine.1">
<a name="Levine.1"></a>Levine WC, Berg AO, Johnson RE, et al. Development of Sexually Transmitted Diseases Treatment Guidelines, 1993. New Methods, Recommendations, and Research Priorities,” STD Treatment Guidelines Project Team and Consultants. <i>Sex Transm Dis</i>. 1994;21(2)(suppl):96-101.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23439909">
<a name="23439909"></a>Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. <i>Pediatrics</i>. 2013;131(3):e964-e999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/23439909/pubmed" id="23439909" target="_blank">23439909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8829204">
<a name="8829204"></a>Mamzoridi K, Kasteridou N, Peonides A, Niopas I. Pharmacokinetics of cefixime in children with urinary tract infections after a single oral dose. <i>Pharmacol Toxicol.</i> 1996;78(6):417-420. doi:10.1111/j.1600-0773.1996.tb00229.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/8829204/pubmed" id="8829204" target="_blank">8829204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7641600">
<a name="7641600"></a>Markham A, Brogden RN. Cefixime. A Review of Its Therapeutic Efficacy in Lower Respiratory Tract Infections. <i>Drugs</i>. 1995;49(6):1007-1022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/7641600/pubmed" id="7641600" target="_blank">7641600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10069359">
<a name="10069359"></a>Marshall WF, Blair JE. The Cephalosporins. <i>Mayo Clin Proc</i>. 1999;74(2):187-195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/10069359/pubmed" id="10069359" target="_blank">10069359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26903277">
<a name="26903277"></a>Moustafa F, Nguyen G, Mathevon T, et al. Evaluation of the efficacy and tolerance of a short 7 day third-generation cephalosporin treatment in the management of acute pyelonephritis in young women in the emergency department. <i>J Antimicrob Chemother</i>. 2016;71(6):1660-1664.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/26903277/pubmed" id="26903277" target="_blank">26903277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8444056">
<a name="8444056"></a>Nahata MC, Kohlbrenner VM, Barson WJ. Pharmacokinetics and cerebrospinal fluid concentrations of cefixime in infants and young children. <i>Chemotherapy</i>. 1993;39(1):1-5. doi:10.1159/000238966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/8444056/pubmed" id="8444056" target="_blank">8444056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18061019">
<a name="18061019"></a>Nicolle LE. Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. <i>Urol Clin North Am</i>. 2008;35(1):1-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/18061019/pubmed" id="18061019" target="_blank">18061019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11397619">
<a name="11397619"></a>Owens RC Jr, Tessier P, Nightingale CH, Ambrose PG, Quintiliani R, Nicolau DP. Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens.<i> Int J Antimicrob Agents.</i> 2001;17(6):483-489. doi:10.1016/s0924-8579(01)00322-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/11397619/pubmed" id="11397619" target="_blank">11397619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20598025">
<a name="20598025"></a>Ozyüncü O, Beksac MS, Nemutlu E, et al. Maternal Blood and Amniotic Fluid Levels of Moxifloxacin, Levofloxacin and Cefixime. <i>J Obstet Gynaecol Res</i>. 2010;36(3):484-487.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/20598025/pubmed" id="20598025" target="_blank">20598025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10870071">
<a name="10870071"></a>Paganini HR, Sarkis CM, De Martino MG, et al. Oral Administration of Cefixime to Lower Risk Febrile Neutropenic Children With Cancer. <i>Cancer</i>. 2000;88(12):2848-2852.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/10870071/pubmed" id="10870071" target="_blank">10870071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17593957">
<a name="17593957"></a>Pandit A, Arjyal A, Day JN, et al. An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever. <i>PLoS One</i>. 2007;2(6):e542.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/17593957/pubmed" id="17593957" target="_blank">17593957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12456854">
<a name="12456854"></a>Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. <i>N Engl J Med</i>. 2002;347(22):1770-1782.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/12456854/pubmed" id="12456854" target="_blank">12456854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Patel.2018">
<a name="Patel.2018"></a>Patel ZM, Hwang PH. Uncomplicated acute sinusitis and rhinosinusitis in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pichichero.1">
<a name="Pichichero.1"></a>Pichichero ME. Treatment and prevention of streptococcal pharyngitis in adults and children. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CANGuidelines.1">
<a name="CANGuidelines.1"></a>Public Health Agency of Canada. Canadian Guidelines on Sexually Transmitted Infections. <a href="https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines.html" target="_blank">https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines.html</a>. Accessed August 8, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to the manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3320921">
<a name="3320921"></a>Risser WL, Barone JS, Clark PA, Simpkins DL. Noncomparative, open label, multicenter trial of cefixime for treatment of bacterial pharyngitis, cystitis and pneumonia in pediatric patients. <i>Pediatr Infect Dis J</i>. 1987;6(10):1002-1006.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/3320921/pubmed" id="3320921" target="_blank">3320921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25832968">
<a name="25832968"></a>Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(2)(suppl):S1-S39. doi:10.1177/0194599815572097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/25832968/pubmed" id="25832968" target="_blank">25832968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11777865">
<a name="11777865"></a>Sanchez M, Collvinent B, Miró O, et al. Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomised controlled trial. <i>Emerg Med J</i>. 2002;19(1):19-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/11777865/pubmed" id="11777865" target="_blank">11777865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8833562">
<a name="8833562"></a>Schatz BS, Karavokiros KT, Taeubel MA, et al. Comparison of Cefprozil, Cefpodoxime Proxetil, Loracarbef, Cefixime, and Ceftibuten. <i>Ann Pharmacother</i>. 1996;30(3):258-268.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/8833562/pubmed" id="8833562" target="_blank">8833562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18057480">
<a name="18057480"></a>Shakur MS, Arzuman SA, Hossain J, Mehdi H, Ahmed M. Cefpodoxime proxetil compared with cefixime for treatment of typhoid fever in children. <i>Indian Pediatr</i>. 2007;44(11):838-841.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/18057480/pubmed" id="18057480" target="_blank">18057480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11112678">
<a name="11112678"></a>Shenep JL, Flynn PM, Baker DK, et al. Oral Cefixime Is Similar to Continued Intravenous Antibiotics in the Empirical Treatment of Febrile Neutropenic Children With Cancer. <i>Clin Infect Dis</i>. 2001;32(1):36-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/11112678/pubmed" id="11112678" target="_blank">11112678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22965026">
<a name="22965026"></a>Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2012;55(10):e86-102. doi:10.1093/cid/cis629<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/22965026/pubmed" id="22965026" target="_blank">22965026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2405586">
<a name="2405586"></a>Smith GH. Oral Cephalosporins in Perspective. <i>DICP</i>. 1990;24(1):45-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/2405586/pubmed" id="2405586" target="_blank">2405586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33332296">
<a name="33332296"></a>St. Cyr S, Barbee L, Workowski KA, et al. Update to CDC's treatment guidelines for gonococcal infection, 2020. <i>MMWR Morb Mortal Wkly Rep</i>. 2020;69(50):1911-1916. doi:10.15585/mmwr.mm6950a6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/33332296/pubmed" id="33332296" target="_blank">33332296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11840084">
<a name="11840084"></a>Stephens I, Levine MM. Management of Typhoid Fever in Children. <i>Pediatr Infect Dis J</i>. 2002;21(2):157-158.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/11840084/pubmed" id="11840084" target="_blank">11840084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Suprax.1">
<a name="Suprax.1"></a>Suprax (cefixime) [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals Inc; October 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Suprax.2">
<a name="Suprax.2"></a>Suprax (cefixime) [product monograph]. Pointe-Claire, Quebec, Canada: Odan Laboratories Ltd; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9675443">
<a name="9675443"></a>Turnidge JD. The pharmacodynamics of beta-lactams. <i>Clin Infect Dis</i>. 1998;27(1):10-22. doi:10.1086/514622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/9675443/pubmed" id="9675443" target="_blank">9675443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17570704">
<a name="17570704"></a>Wagner LM, Crews KR, Stewart CF, et al. Reducing Irinotecan-Associated Diarrhea in Children. <i>Pediatr Blood Cancer</i>. 2008;50(2):201-207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/17570704/pubmed" id="17570704" target="_blank">17570704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23796742">
<a name="23796742"></a>Wald ER, Applegate KE, Bordley C, et al; American Academy of Pediatrics. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years. <i>Pediatrics</i>. 2013;132(1):e262-e280.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/23796742/pubmed" id="23796742" target="_blank">23796742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA; Centers for Disease Control and Prevention (CDC). Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep. </i>2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Background Document: The Diagnosis, Treatment and Prevention of Typhoid Fever. May 2003. http://apps.who.int/iris/bitstream/10665/68122/1/WHO_V-B_03.07_eng.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30535100">
<a name="30535100"></a>Yahav D, Franceschini E, Koppel F, et al; Bacteremia Duration Study Group. Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial. <i>Clin Infect Dis</i>. 2019;69(7):1091-1098. doi:10.1093/cid/ciy1054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefixime-pediatric-drug-information/abstract-text/30535100/pubmed" id="30535100" target="_blank">30535100</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13127 Version 261.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
